Perrigo Company Stock News

Perrigo Company said on Monday its unit has submitted an application to the U.S. Food and Drug Administration (FDA) for approval of an over-the-counter (OTC) birth control pill.

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Self-care health and wellness products make Perrigo (NASDAQ: PRGO) stock has been recovering well off its $31.22 bottom.

President Joe Biden on Wednesday is slated to meet with executives from baby-formula makers, with the huddle coming as new data suggest that the country's formula shortage is deepening.

DUBLIN , May 19, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Murray S. Kessler and CFO Eduardo Bez

Perrigo Company plc (NYSE:PRGO ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bradley Joseph - Vice President of Investor Relations Murray Kessler - President and Chie

Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly

Perrigo (PRGO) delivered earnings and revenue surprises of -21.43% and 1.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo PLC shares PRGO, +0.37% slid 4% in premarket trade Wednesday, after the personal self-care product maker swung to a loss for the first quarter and fell short of estimates. The Dublin-based Per

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DUBLIN , April 27, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its first quarter 2022 financial resul

Pune, India, March 03, 2022 (GLOBE NEWSWIRE) -- The global OTC drugs market size is projected to grow from USD 157.0 billion in 2021 to USD 233.6 billion in 2028. The rising number of private label products is set to affect growth positively. In the U.S., shares of these products reached 31.0% in 2018 from 26.0% in 2009. Also, numerous companies are collaborating with e-commerce platforms to launch their products on their platforms. Amazon.com, Inc., for instance, introduced Perrigo''s over-the-counter healthcare products in February 2018. Fortune Business Insights™ mentioned this in a published report, titled, "OTC Drugs Market, 2021-2028." The report further states that the market stood at USD 148.0 billion in 2020. It is set to showcase a CAGR of 5.8% in the forecast period during 2021-2028. Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/over-the-counter-otc-drugs-market-105433 Report Scope & Segmentation Report Coverage Details Forecast Period 2021-2028 Forecast Period 2021 to 2028 CAGR 5.8% 2028 Value Projection USD 233.6 Billion Base Year 2020 Market Size in 2021 USD 29.63 Billion Historical Data for 2017-2019 No. of Pages 140 Segments covered By Type, …

Major players in the clinical nutrition market are Abbott Laboratories, Nestlé SA, Baxter Healthcare Ltd. , B. Braun Melsungen AG, Perrigo Company Plc. , Hospira, Fresenius Kabi, Danone, Pfizer and Mead Johnson Nutrition Company. Major players in the clinical nutrition market are Abbott Laboratories, Nestlé SA, Baxter Healthcare Ltd. , B. Braun Melsungen AG, Perrigo Company Plc. , Hospira, Fresenius Kabi, Danone, Pfizer and Mead Johnson Nutrition Company.

The company recovered nicely from the challenges of the coronavirus pandemic, as indicated by its Q4 results.